William Blair & Company
AERI

William Blair & Company’s Aerie Pharmaceuticals AERI Stock Holding History

William Blair & Company’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,623
Closed -$155K – 2035
2021
Q3 		$155K Buy
+13,623
New +$199K ﹤0.01% 1549

Other funds holding AERI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

William Blair & Company's AERI Position: Q4 2021 in Review

William Blair & Company sold out of Aerie Pharmaceuticals (AERI) in Q4 2021, closing a stake of 13,623 shares — an estimated $155K sold.

William Blair & Company first reported a position in AERI in Q3 2021 and held it in 1 quarter. The position peaked at $155K in Q3 2021. 129 funds tracked by Wall St. Rank hold AERI as of Q4 2021.

  • William Blair & Company reported no remaining Aerie Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • William Blair & Company sold 13,623 Aerie Pharmaceuticals shares in Q4 2021, an estimated $155K.
  • William Blair & Company first reported a position in Aerie Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • William Blair & Company's Aerie Pharmaceuticals position peaked at $155K in Q3 2021.
  • 129 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2021.

Based on William Blair & Company's 13F filing for Q4 2021, filed 14 Feb 2022.